08:00 , Feb 7, 2011 |  BC Week In Review  |  Clinical News

BioCancell preclinical data

In a mouse model of glioblastoma, BC-821 significantly reduced tumor growth by 60% compared to untreated controls. BC-821 is a plasmid that activates the synthesis of diphtheria toxin in cancer cells expressing either the insulin-like...
07:00 , May 26, 2008 |  BC Week In Review  |  Company News

BioCancell, Pro-Pharmaceuticals deal

The companies partnered to develop BioCancell’s BC-819 plasmid with Pro-Pharmaceuticals’ Davanat delivery system to treat cancer. Pro-Pharmaceuticals will conduct and fund in vivo and in vitro tests of the combination, and the companies will share...